Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

449.83 -0.54 (-0.12%)
Streaming Delayed Price Updated: 11:06 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Why We Buy Stocks
Is fear of missing out (FOMO) controlling your portfolio? 
Via The Motley Fool
Prediction: These 2 Stocks Will Beat the S&P 500 Through 2030
There's no need to change a winning formula. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Market Whales and Their Recent Bets on VRTX Options
Via Benzinga
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
What Analysts Are Saying About Vertex Pharmaceuticals Stock
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today
Via Benzinga
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)
Via Benzinga
Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
Got $1,000? 2 Magnificent Growth Stocks to Buy and Hold Forever
These profitable companies are facing long-term growth runways. 
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in October
These stocks look like slam-dunk picks for growth investors. 
Via The Motley Fool
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
Via Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
2 Biotech Stocks to Buy Hand Over Fist in October
These longtime leading biotech stocks still have plenty of upside ahead. 
Via The Motley Fool
Cathie Wood's Ark Invest Trades: Bets $14M On Amazon Shares — Dumps Robinhood Stock Worth $36M, Embraces Coinbase And Meta
Cathie Wood's Ark Invest made significant trades in Amazon.com Inc (NASDAQ: AMZN), Robinhood Markets Inc (NASDAQ: HOOD), and Coinbase Global Inc (NASDAQ: COIN) on Tuesday Oct 8, 2024. 
Via Benzinga
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Insider Trades: How To Find The Top Stocks
There are dozens of insider trades going on every week. Here are 5 insider stock buys that stand out. 
Via Talk Markets
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
Via The Motley Fool
2 Superior Growth Stocks That Are Screaming Buys Right Now
These companies have plenty of growth runway left. 
Via The Motley Fool
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Best Biotech Stock to Invest $1,000 in Right Now
Vertex Pharmaceuticals isn't an ordinary biotech stock. 
Via The Motley Fool
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Great companies have persisted even in a tumultuous market. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. 
Via The Motley Fool
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
Prediction: These 3 Phenomenal Stocks Are Set to Soar
These stocks are already solid winners in 2024. They should be able to keep the momentum going. 
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.